Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 36; no. 15_suppl; p. 7560
Main Authors Huang, He, Li, Xue Ying, Hong, Huang Ming, Wang, Zhao, Fang, Xiaojie, Li, Fangfang, Peng, Chen, Ren, Quanguang, Sha, Fushen, Zhang, Limei, Lin, Suxia, Liu, Qing, Lin, Tongyu
Format Journal Article
LanguageEnglish
Published 20.05.2018
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2018.36.15_suppl.7560